Tristen Moors

Tristen Moors has been working in clinical operations and development for 20+ years. She has been fortunate to focus the majority of her clinical operations career in rare disease, including urea cycle disorders (UCDs), X-linked myotubular myopathy (XLMTM), thymidine kinase 2 deficiency (TK2d), and congenital muscular dystrophies (CMDs). She was most recently Vice President of Clinical Operations at Prothelia. Prior to Prothelia, she was Head of Clinical Operations at Modis Therapeutics until its acquisition by Zogenix. Ms. Moors received her M.S. in marine science from UC Santa Cruz and B.S. in biology from Santa Clara University.